WO1999046244A1 - Modulateurs de proteine tyrosine phosphatases (ptpases) - Google Patents

Modulateurs de proteine tyrosine phosphatases (ptpases) Download PDF

Info

Publication number
WO1999046244A1
WO1999046244A1 PCT/DK1999/000123 DK9900123W WO9946244A1 WO 1999046244 A1 WO1999046244 A1 WO 1999046244A1 DK 9900123 W DK9900123 W DK 9900123W WO 9946244 A1 WO9946244 A1 WO 9946244A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
oxalyl
carboxylic acid
thiophene
alkyl
Prior art date
Application number
PCT/DK1999/000123
Other languages
English (en)
Inventor
Lone Jeppesen
Henrik Sune Andersen
Ole Hvilsted Olsen
Luke Milburn Judge
Daniel Dale Holsworth
Farid Bakir
Frank Urban Axe
Yu Ge
Original Assignee
Novo Nordisk A/S
Ontogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S, Ontogen Corporation filed Critical Novo Nordisk A/S
Priority to EP99907334A priority Critical patent/EP1062204A1/fr
Priority to JP2000535625A priority patent/JP2002506058A/ja
Priority to AU27137/99A priority patent/AU2713799A/en
Publication of WO1999046244A1 publication Critical patent/WO1999046244A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1 B, CD45, SHP-1 , SHP-2, PTP ⁇ , LAR and HePTP or the like,
  • PTPases Protein Tyrosine Phosphatases
  • R 1 f R 2 , R 3 , R 4> R 16 and R 17 are defined more fully below.
  • PTPases plays a major role in the intracellular modulation and regulation of fundamental cellular signalling mechanisms involved in metabolism, growth, proliferation and differentiation (Flint et al., The EMBO J. 12:1937-46 (1993); Fischer et al, Science 253:401-6 (1991)). Overexpression or altered activity of tyrosine phosphatases can also contribute to the symptoms and progression of various diseases (Wiener, et al., J. Natl. cancer Inst. 86:372-8 (1994); Hunter and Cooper, Ann. Rev. Biochem, 54:897-930 (1985)). Furthermore, there is increasing evidence which suggests that inhibition of these PTPases may help treat certain types of diseases such as diabetes type I and II, autoimmune disease, acute and chronic inflammation, osteoporosis and various forms of cancer. 2
  • Protein phosphorylation is now well recognized as an important mechanism utilized by cells to transduce signals during different stages of cellular function (Fischer et al, Science 253:401-6 (1991); Flint et al., The EMBO J. 12:1937-46 (1993)).
  • phosphatases There are at least two major classes of phosphatases: (1) those that dephosphorylate proteins (or peptides) that contain a phosphate group(s) on a serine or threonine moiety (termed SerfThr phosphatases) and (2) those that remove a phosphate group(s) from the amino acid tyrosine (termed protein tyrosine phosphatases or PTPases).
  • the PTPases are a family of enzymes that can be classified into two groups: a) intracellular or nontransmembrane PTPases and b) receptor-type or transmembrane PTPases.
  • Intracellular PTPases Most known intracellular type PTPases contain a single conserved catalytic phosphatase domain consisting of 220-240 amino acid residues. The regions outside the PTPase domains are believed to play important roles in localizing the intracellular PTPases subcellularly (Mauro, L.J. and Dixon, J.E. TIBS 19: 151-155 (1994)). The first intracellular PTPase to be purified and characterized was PTP1B which was isolated from human placenta (Tonks et al., J. Biol. Chem. 263: 6722-6730 (1988)). Shortly after, PTP1B was cloned (Charbonneau et al., Proc.
  • intracellular PTPases include (1) T-cell PTPase (Cool et al. Proc. Natl. Acad. Sci. USA 86: 5257-5261 (1989)), (2) rat brain PTPase (Guan et al., Proc. Natl. Acad. Sci. USA 87:1501-1502 (1990)), (3) neuronal phosphatase STEP (Lombroso et al., Proc. Natl. Acad. Sci.
  • LMW-PTPase Low molecular weight phosphotyrosine-protein phosphatase shows very little sequence identity to the intracellular PTPases described above.
  • this enzyme belongs to the PTPase family due to the following characteristics: (i) it possesses the PTPase active site motif: Cys-Xxx-Xxx-Xxx- Xxx-Xxx-Arg (Cirri et al., Eur. J. Biochem. 214: 647-657 (1993)); (ii) this Cys residue forms a phospho-intermediate during the catalytic reaction similar to the situation with 'classical' PTPases (Cirri et al., supra; Chiarugi et al., FEBS Lett.
  • Receptor-type PTPases consist of a) a putative ligand-binding extracellular domain, b) a transmembrane segment, and c) an intracellular catalytic region.
  • the structures and sizes of the putative ligand-binding extracellular domains of receptor-type PTPases are quite divergent.
  • the intracellular catalytic regions of receptor-type PTPases are very homologous to each other and to the intracellular PTPases.
  • Most receptor-type PTPases have two tandemly duplicated catalytic PTPase domains.
  • the first receptor-type PTPases to be identified were (1) CD45/LCA (Ralph, S.J., EMBO J. 6: 1251-1257 (1987)) and (2) LAR (Streuli et al., J. Exp. Med. 168: 1523-1530 (1988)) that were recognized to belong to this class of enzymes based on homology to PTP1 B (Charbonneau et al., Proc. Natl. Acad. Sci. USA 86: 5252- 5256 (1989)).
  • CD45 is a family of high molecular weight glycoproteins and is one 4 of the most abundant leukocyte cell surface glycoproteins and appears to be exclusively expressed upon cells of the hematopoietic system (Trowbridge and Thomas, Ann. Rev. Immunol. 12: 85-116 (1994)).
  • PTPa,_PTPe All receptor-type PTPases except Type IV contain two PTPase domains. Novel PTPases are continuously identified, and it is anticipated that more than 500 different species will be found in the human genome, i.e. close to the predicted size of the protein tyrosine kinase superfamily (Hanks and Hunter, FASEB J. 9: 576-596 (1995)).
  • PTPases are the biological counterparts to protein tyrosine kinases (PTKs). Therefore, one important function of PTPases is to control, down-regulate, the activity of PTKs.
  • PTKs protein tyrosine kinases
  • a more complex picture of the function of PTPases now emerges.
  • Several studies have shown that some PTPases may actually act as positive mediators of cellular signalling.
  • the SH2 domain- containing PTP1 D seems to act as a positive mediator in insulin-stimulated Ras activation (Noguchi et al., Mol. Ceil. Biol. 14: 6674-6682 (1994)) and of growth 5 factor-induced mitogenic signal transduction (Xiao et al., J. Biol. Chem.
  • PTPases as positive regulators has been provided by studies designed to define the activation of the Src-family of tyrosine kinases. In particular, several lines of evidence indicate that CD45 is positively regulating the activation of hematopoietic cells, possibly through dephosphorylation of the C-terminal tyrosine of Fyn and Lck (Chan et al., Annu. Rev. Immunol. 12: 555-592 (1994)).
  • Dual specificity protein tyrosine phosphatases define a subclass within the PTPases family that can hydrolyze phosphate from phosphortyrosine as well as from phosphor-serine/threonine.
  • dsPTPases contain the signature sequence of PTPases: His-Cys-Xxx-Xxx-Gly-Xxx-Xxx-Arg. At least three dsPTPases have been shown to dephosphorylate and inactivate extracellular signal-regulated kinase (ERKs)/mitogen-activated protein kinase (MAPK): MAPK phosphatase (CL100, 3CH134) (Charles et al., Proc. Natl.
  • dsPTPases Transcription of dsPTPases are induced by different stimuli, e.g. oxidative stress or heat shock (Ishibashi et al., J. Biol. Chem. 269: 29897-29902 (1994); Keyse and Emslie, Nature 359: 644-647 (1992)).
  • stimuli e.g. oxidative stress or heat shock (Ishibashi et al., J. Biol. Chem. 269: 29897-29902 (1994); Keyse and Emslie, Nature 359: 644-647 (1992)).
  • cdc25 Millar and Russell, Cell 68: 407-410 (1992)
  • KAP Hannon et al., Proc. Natl. Acad. Sci. USA 91: 1731-1735 (1994)
  • tyrosine dephosphorylation of cdc2 by a dual specific phosphatase, cdc25 is required for induction of mitosis in yeast (review by Walton and Dixon, Annu. Rev. Biochem. 62: 101-120 (1993)).
  • PTPases were originally identified and purified from cell and tissue lysates using a variety of artificial substrates and therefore their natural function of dephosphorylati- on was not well known. Since tyrosine phosphorylation by tyrosine kinases is usually 6 associated with cell proliferation, cell transformation and cell differentiation, it was assumed that PTPases were also associated with these events. This association has now been proven to be the case with many PTPases.
  • PTP1 B a phosphatase whose structure was recently elucidated (Barford et al., Science 263:1397-1404 (1994)) has been shown to be involved in insulin-induced oocyte maturation (Flint et al., The EMBO J.
  • PTPases the insulin receptor signalling pathway/diabetes
  • Insulin is an important regulator of different metabolic processes and plays a key role in the control of blood glucose. Defects related to its synthesis or signalling 7 lead to diabetes mellitus. Binding of insulin to its receptor causes rapid (auto)phosphorylation of several tyrosine residues in the intracellular part of the b- subunit. Three closely positioned tyrosine residues (the tyrosine-1150 domain) must all be phosphorylated to obtain full activity of the insulin receptor tyrosine kinase (IRTK) which transmits the signal further downstream by tyrosine phosphorylation of other cellular substrates, including insulin receptor substrate-1 (IRS-1) (Wilden et al., J. Biol. Chem.
  • IRTK appears to be tightly regulated by PTP- mediated dephosphorylation in vivo (Khan et al., J. Biol. Chem. 264: 12931-12940 (1989); Faure et al., J. Biol. Chem. 267: 11215-11221 (1992); Rothenberg et al., J. Biol. Chem. 266: 8302-8311 (1991)).
  • PTPases have distinct structural features that determine their subcellular localization and thereby their access to defined cellular substrates (Frangione et al., Cell 68: 545-560 (1992); Faure and Posner, Glia 9: 311-314 (1993)).
  • PTP1B and TC-PTP have been excluded as candidates for the IR-associated PTPases in hepatocytes based on subcellular localization studies (Faure et al., J. Biol. Chem. 267: 11215-11221 (1992)).
  • the transmembrane PTPase CD45 which is believed to be hematopoietic cell- specific, was in a recent study found to negatively regulate the insulin receptor tyrosine kinase in the human multiple myeloma cell line U266 (Kulas et al., J. Biol. Chem. 271: 755-760 (1996)).
  • Somatostatin inhibits several biological functions including cellular proliferation (Lamberts et al., Molec. Endocrinol. 8: 1289-1297 (1994)). While part of the antiproliferative activities of somatostatin are secondary to its inhibition of hormone and growth factor secretion (e.g. growth hormone and epidermal growth factor), other antiproliferative effects of somatostatin are due to a direct effect on the target cells. As an example, somatostatin analogs inhibit the growth of pancreatic cancer presumably via stimulation of a single PTPase, or a subset of PTPases, rather than a general activation of PTPase levels in the cells (Liebow et al., Proc. Natl.
  • PTPases the immune system/autoimmunity
  • CD45 is one of the most abundant of the cell surface glycoproteins and is expressed exclusively on hemopoetic cells. In T cells, it has been shown that CD45 is one of the critical components of the signal transduction machinery of lymphocytes. In particular, evidence has suggested that CD45 phosphatase plays a pivotal role in antigen- stimulated proliferation of T lymphocytes after an antigen has bound to the T cell receptor (Trowbridge, Ann. Rev. Immunol, 12:85-116 (1994)). Several studies suggest 11 that the PTPase activity of CD45 plays a role in the activation of Lck, a lymphocyte- specific member of the Src family protein-tyrosine kinase (Mustelin etal., Proc. Natl. Acad.
  • the p56lck-CD45 interaction seems to be mediated via a nonconventional SH2 domain interaction not requiring phosphotyrosine.
  • Fyn another member of the Src family protein-tyrosine kinases, Fyn, seems to be a selective substrate for CD45 compared to Lck and Syk (Katagiri et al., J. Biol. Chem. 270: 27987-27990 (1995)).
  • CD45 has also been shown to be essential for the antibody mediated degranulation of mast cells (Berger et al., J. Exp. Med. 180:471-6 (1994)). These studies were also done with mice that were CD45-deficient. In this case, an IgE-mediated degranulation was demonstrated in wild type but not CD45-deficient T cells from mice. These data suggest that CD45 inhibitors could also play a role in the symptomatic or therapeutic treatment of allergic disorders.
  • HePTP lymphoid-specific protein tyrosine phosphatase
  • HePTP may function during sustained stimulation to modulate the immune response through dephosphorylation of specific residues. Its exact role, however remains to be defined.
  • PTPase inhibitors may be attractive drug candidates both as immunosuppressors and as immunostimulants.
  • BMLOV vanadium-based PTPase inhibitor
  • PTPases cell-cell interactions/cancer
  • Focal adhesion plaques an in vitro phenomenon in which specific contact points are formed when fibroblasts grow on appropriate substrates, seem to mimic, at least in part, cells and their natural surroundings.
  • Several focal adhesion proteins are phosphorylated on tyrosine residues when fibroblasts adhere to and spread on extracellular matrix (Gumbiner, Neuron 11, 551-564 (1993)).
  • Aberrant tyrosine phosphorylation of these proteins can lead to cellular transformation.
  • the intimate association between PTPases and focal adhesions is supported by the finding of several intracellular PTPases with ezrin-like N-terminal domains, e.g. PTPMEG1 (Gu et al., Proc. Natl. Acad. Sci.
  • PTPH1 Yang and Tonks, Proc. Natl. Acad. Sci. USA 88: 5949-5953 (1991)
  • PTPD1 Yang and Tonks, Proc. Natl. Acad. Sci. USA 88: 5949-5953 (1991)
  • PTPD1 M ⁇ ller et al., Proc. Natl. Acad. Sci. USA 91: 7477-7481 (1994)
  • the ezrin-like domain show similarity to several proteins that are believed to act as links between the cell membrane and the cytoskeleton.
  • PTPD1 was found to be phosphorylated 13 by and associated with c-src in vitro and is hypothesized to be involved in the regulation of phosphorylation of focal adhesions (M ⁇ ller et al., supra).
  • PTPases may oppose the action of tyrosine kinases, including those responsible for phosphorylation of focal adhesion proteins, and may therefore function as natural inhibitors of transformation.
  • TC-PTP and especially the truncated form of this enzyme (Cool et al., Proc. Natl. Acad. Sci. USA 87: 7280-7284 (1990)), can inhibit the transforming activity of ⁇ -erb and v-fms (Lammers et al., J. Biol. Chem.
  • PTP1B The expression level of PTP1B was found to be increased in a mammary cell line transformed with neu (Zhay et al., Cancer Res. 53: 2272-2278 (1993)).
  • the intimate relationship between tyrosine kinases and PTPases in the development of cancer is further evidenced by the recent finding that PTPe is highly expressed in murine mammary tumors in transgenic mice over-expressing c-neu and v-Ha-ras, but not c-myc or int-2 (Elson and Leder, J. Biol. Chem. 270: 26116-26122 (1995)).
  • PTPases Two closely related receptor-type PTPases, PTPK and PTP ⁇ , can mediate homophilic cell-cell interaction when expressed in non-adherent insect cells, suggesting that these PTPases might have a normal physiological function in cell- to-cell signalling (Gebbink et al., J. Biol. Chem. 268: 16101-16104 (1993); Brady- Kalnay et al., J. Cell Biol. 122: 961 -972 (1993); Sap et al., Mol. Cell. Biol. 14: .-9 (1994)).
  • PTPk and PTP ⁇ do not interact with each other, despite their structural similarity (Zondag et al, J. Biol. Chem.
  • PTPases may play an important role in regulating normal cell growth.
  • PTPases may also function as positive mediators of intracellular signalling and thereby induce or enhance mitogenic responses. Increased activity of certain PTPases might therefore result in cellular transformation and tumor formation.
  • over-expression of PTP ⁇ was found to lead to transformation of rat embryo fibroblasts (Zheng, supra).
  • SAP-1 a novel PTP, SAP-1 , was found to be highly expressed in pancreatic and colorectal cancer cells.
  • SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2 (Uchida ef al., J. Biol. Chem. 269: 12220-12228 (1994)). Further, the dsPTPase, cdc25, dephosphorylates cdc2 at Thr14/Tyr-15 and thereby functions as positive regulator of mitosis (reviewed by Hunter, Cell 80: 225-236 (1995)). Inhibitors of specific PTPases are therefore likely to be of significant therapeutic value in the treatment of certain forms of cancer.
  • PTPases platelet aggregation 15
  • PTPases are centrally involved in platelet aggregation.
  • Agonist-induced platelet activation results in calpain-catalyzed cleavage of PTP1B with a concomitant 2-fold stimulation of PTPase activity (Frangioni et al., EMBO J. 12: 4843-4856 (1993)).
  • the cleavage of PTP1 B leads to subcellular relocation of the enzyme and correlates with the transition from reversible to irreversible platelet aggregation in platelet-rich plasma.
  • the SH2 domain containing PTPase, SHP-1 was found to translocate to the cytoskeleton in platelets after thrombin stimulation in an aggregation-dependent manner (Li et al., FEBS Lett. 343: 89-93 (1994)).
  • the rate of bone formation is determined by the number and the activity of osteoblasts, which in term are determined by the rate of proliferation and differentiation of osteoblast progenitor cells, respectively. Histomorphometric studies indicate that the osteoblast number is the primary determinant of the rate of bone formation in humans (Gruber et al., Mineral Electrolyte Metab. 12: 246-254 (1987); reviewed in Lau et al., Biochem. J. 257: 23-36 (1989)). Acid phosphatases/PTPases may be involved in negative regulation of osteoblast proliferation. Thus, fluoride, which has phosphatase inhibitory activity, has been found to increase spinal bone density in osteoporotics by increasing osteoblast proliferation (Lau et al., supra).
  • PTPase inhibitors may prevent differentiation via inhibition of OST-PTP or other PTPases thereby leading to continued proliferation. This would be in agreement with the above-mentioned effects of fluoride and the observation that the tyrosine phosphatase inhibitor orthovanadate appears to enhance osteoblast proliferation and matrix formation (Lau et al., Endocrinology 116: 2463- 2468 (1988)).
  • vanadate, vanadyl and pervanadate all increased the growth of the osteoblast-like cell line UMR106. Vanadyl and pervanadate were stronger stimulators of cell growth than vanadate. Only vanadate was able to regulate the cell differentiation as measured by cell alkaline phosphatase activity (Cortizo et al., Mol. Cell. Biochem. 145: 97-102 (1995)).
  • the present invention relates to compounds of the general formula I, wherein A, R 1 ( R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the detailed part of the present description, wherein such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1 B, CD45, SHP-1 , SHP-2, PTP ⁇ , LAR and HePTP or the like.
  • PTPases Protein Tyrosine Phosphatases
  • the present compounds are useful for the treatment, prevention, elimination, alleviation or amelioration of an indication related to type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the 18 general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the method of treatment may be described as the treatment, prevention, elimination, alleviation or amelioration of one of the above indications, which comprises the step of administering to the said subject a neurologically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • a further aspect of the invention relates to the use of a compound of the present in- vention for the preparation of a pharmaceutical composition for the treatment of all type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or in- creased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases. 19 DESCRIPTION OF THE INVENTION
  • the present invention relates to Compounds of the Formula 1 wherein A, R 1 t R 2 , R 3 , R 4 , R 16 and R 17 are defined below;
  • A is together with the double bond in Formula 1 furanyl, thiophenyl, pyrrolyl, oxa- zolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1 ,2,3-oxadiazolyl, fu- razanyl or 1 ,2,3-triazolyl;
  • R 1 is hydrogen, COR 5 , OR 6 , CF 3 , nitro, cyano, S0 3 H, SO 2 NR 7 R 8 , PO(OH) 2 ,
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C 6 alkyl, aryl, arylC r C 6 -alkyl, hydroxy, oxo, carboxy, carboxyC 1 -C 6 alkyl, C r C 6 alkyloxycarbonyl, aryloxycarbonyl, arylC r C 6 alkyloxycarbonyl, C,-C 6 alkyloxy, C r C 6 alkyloxyC r C 6 alkyl, aryloxy, arylC C 6 alkyloxy, arylC 1 -C 6 alkyloxyC 1 -C 6 alkyl, thio, C C 6 alkylthio, C r C ⁇ alkylthioC C ⁇ al yl, arylthio, arylC 1 -C 6 alkylthio, arylC 1 -C 6 alkylthioC 1 - C
  • D is a chemical bond, amino or C C 8 alkyl wherein the alkyl and aryl groups are optionally substituted;
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC r C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C C 6 alkyl, aryl, arylC r C 6 alkyl, NR 7 R 8 , C r C 6 alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C C 6 alkyl, aryl, arylC r C 6 alkyl, C r C 6 alkyloxy, C r C 6 alkyl-oxyC.,- C 6 alkyloxy, aryloxy, arylC C 6 alkyloxy, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C C 6 alkyl, aryl, arylC C 6 alkyl; wherein the alkyl and aryl groups are optionally substituted; 22
  • R 7 and R 8 are independently selected from hydrogen, C C 6 alkyl, adamantyl, aryl, a- rylC r C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC 1 -C 6 alkylcarbonyl, C r C 6 alkylcarboxy or arylC ⁇ Cgalkylcarboxy wherein the alkyl and aryl groups are optio- nally substituted; or
  • R 7 and R 8 are taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C r C 6 alkyl, aryl, arylC ⁇ Cgalkyl, hydroxy, oxo, C 1 -C 6 alkyloxy, arylC ⁇ Cgalkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, NR 9 R 10 or C 1 -C 6 alkylaminoC 1 -C 6 alkyl, wherein R 9 and R 10 are independently selected from hydrogen, C r C 6 alkyl, aryl, arylC,-C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC C 6 alkylcarbonyl, C,-
  • any optical iso- mer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • Signal transduction is a collective term used to define all cellular processes that follow the activation of a given cell or tissue.
  • Examples of signal transduction which are not intended to be in any way limiting to the scope of the invention claimed, are cellular events that are induced by polypeptide hormones and growth factors (e.g. insulin, insulin-like growth factors I and II, growth hormone, epidermal growth factor, platelet-derived growth factor), cytokines (e.g. interleukins), extra- cellular matrix components, and cell-cell interactions.
  • Phosphotyrosine recognition units/tyrosine phosphate recognition units/pTyr recognition units are defined as areas or domains of proteins or gly- coproteins that have affinity for molecules containing phosphorylated tyrosine residues (pTyr).
  • Examples of pTyr recognition units which are not intended to be in any way limiting to the scope of the invention claimed, are: PTPases, SH2 domains and PTB domains.
  • PTPases are defined as enzymes with the capacity to dephosphorylate pTyr- containing proteins or glycoproteins.
  • Examples of PTPases which are not intended to be in any way limiting to the scope of the invention claimed, are: 'classical' PTPases (intracellular PTPases (e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1 , PTPD2) and receptor-type PTPases (e.g. PTP ⁇ , PTP ⁇ , PTP ⁇ , PTP ⁇ , CD45, PTPK, PTP ⁇ ), dual speci- ficty phosphatases (VH1, VHR, cdc25), LMW-PTPases or acid phosphatases.
  • intracellular PTPases e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1 , PTPD2
  • receptor-type PTPases e.g. PTP ⁇ , P
  • SH2 domains are non-catalytic protein modules that bind to pTyr (phosphotyrosine residue) containing proteins, i.e. SH2 domains are pTyr recognition units. SH2 domains, which consist of ⁇ 100 amino acid residues, are found in a number of different molecules involved in signal transduction processes. The following is a non-limiting list of proteins containing SH2 domains: Src, Hck, Lck, Syk, Zap70, SHP-1 , SHP-2, STATs, Grb-2, She, p85/PI3K, Gap, vav (see Russell et al, FEBS Lett. 304:15-20 (1992); Pawson, Nature 373: 573-580 (1995); Sawyer, Biopolymers (Peptide Science) 47: 243-261 (1998); and references herein).
  • the term "attached” or "-" e.g. -COR ⁇ which indicates the carbonyl attachment point to the scaffold
  • halogen include fluorine, chlorine, bromine, and iodine.
  • alkyl includes C C 6 or C C 8 straight chain saturated and C 2 -C 8 unsaturated aliphatic hydrocarbon groups, C C 6 or C ⁇ Cg branched saturated and C 2 -C 6 or C 2 -C 8 unsaturated aliphatic hydrocarbon groups, C 3 -C 6 or C 3 -C 8 cyclic saturated and C 5 -C 6 or C 5 -C 8 unsaturated aliphatic hydrocarbon groups, and C C 6 or C C 8 straight 24 chain or branched saturated and C 2 -C 6 or C 2 -C 8 straight chain or branched unsaturated aliphatic hydrocarbon groups substituted with C 3 -C 6 cyclic saturated and unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • this definition shall include but is not limited to methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, heptyl, octyl, ethenyl, propenyl, butenyl, penentyl, hexenyl, octenyl, isopropyl (i-Pr), isobutyl (i-Bu), tert-butyl (f-Bu), sec-butyl (s-Bu), isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cy- clopentenyl, cyclohexenyl, methylcyclopropyl, ethylcyclohexenyl, butenylcyclopentyl, and the like.
  • substituted alkyl represents an alkyl group as defined above wherein the substitutents are independently selected from halo, cyano, nitro, trihalomethyl, car- bamoyl, hydroxy, oxo, COR 5 , C C 6 alkyl, C 1 -C 6 alkyloxy, aryloxy, arylC.-Cgalkyloxy, thio, C r C 6 alkylthio, arylthio, arylC,-C 6 alkylthio, NR 7 R 8 , C ⁇ Cealkylamino, arylamino, arylC r C 6 alkylamino, di(arylC C 6 alkyl)amino, C C 6 alkylcarbonyl, arylC C 6 alkylcarbonyl, C C 6 alkyl-carboxy, arylC C 6 alkylcarboxy, C.,-C 6 alkylcarbonylamino, -
  • saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system represents but are not limit to aziridinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imida- zolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, 1 ,2,3-triazolyl, 1 ,2,4- triazolyl, morpholinyl, piperidinyl, thiomorpholinyl, piperazinyl, indolyl, isoindolyl, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4-tetrahydro- quinoxalinyl, indolinyl, indazolyl, benzimidazolyl, benzotriazolyl, purinyl, carbazo
  • alkyloxy (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) repre- sents an "alkyl” group as defined above having the indicated number of carbon atoms attached through an oxygen bridge.
  • alkyloxyalkyl represents an 25
  • alkyloxy group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkyloxyalkyloxy represents an “alkyloxyalkyl” group attached through an oxygen atom as defined above having the indicated number of carbon atoms.
  • aryloxy e.g. phenoxy, naphthyloxy and the like
  • arylalkyloxy (e.g. phenethyloxy, naphthylmethyloxy and the like) represents an “arylalkyl” group as defined below attached through an oxygen bridge.
  • arylalkyloxyalkyl represents an "arylalkyloxy” group as defined above at- tached through an "alkyl” group defined above having the indicated number of carbon atoms.
  • arylthio e.g. phenylthio, naphthylthio and the like
  • alkyloxycarbonyl e.g. methylformiat, ethylformiat and the like
  • aryloxycarbonyl e.g. phenylformiat, 2-thiazolylformiat and the like
  • arylalkyloxycarbonyl e.g. benzylformiat, phenyletylformiat and the like
  • alkyloxycarbonylalkyl represents an "alkyloxycarbonyl” group as defined above attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkyloxycarbonylalkyl represents an "arylalkyloxycarbonyl” group as defined above attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • alkylthio (e.g. methylthio, ethylthio, propylthio, cyclohexenylthio and the like) represents an “alkyl” group as defined above having the indicated number of carbon atoms attached through a sulfur bridge.
  • arylalkylthio (e.g. phenylmethylthio, phenylethylthio, and the like) represents an “arylalkyl” group as defined above having the indicated number of carbon atoms attached through a sulfur bridge.
  • alkylthioalkyl represents an "alkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkylthioalkyl represents an "arylalkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkylamino e.g. methylamino, diethylamino, butylamino, N-propyl-N- hexylamino, (2-cyclopentyl)propylamino, hexenylamino, pyrrolidinyl, piperidinyl and the like
  • alkylamino represents one or two "alkyl” groups as defined above having the indicated number of carbon atoms attached through an amine bridge.
  • the two alkyl groups may be taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C r C 6 alkyl, aryl, arylC 1 -C 6 alkyl, hydroxy, oxo, C C 6 alkyloxy, arylC C 6 alkyloxy, C,- C 6 alkyloxyC C 6 alkyl, NR g R 10 or C 1 -C 6 alkylaminoC 1 -C 6 alkyl, wherein R 9 and R 10 are independently selected from hydrogen, C 1 -C 6 alkyl, aryl, arylC C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC r C 6 alkylcarbonyl, C C 6
  • arylalkylamino e.g. benzylamino, diphenylethylamino and the like repre- sents one or two "arylalkyl” groups as defined above having the indicated number of carbon atoms attached through an amine bridge.
  • the two "arylalkyl” groups may be taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C.,-C 6 alkyl, aryl, arylC 1 -C 6 alkyl, hydroxy, oxo, C r C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, NR 9 R 10 , C r 27
  • alkylaminoalkyl represents an "alkylamino” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkylaminoalkyl represents an "arylalkylamino” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkyl (e.g.
  • alkylcarbonyl e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-hexenylcarbonyl
  • alkylcarbonyl represents an "alkyl” group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
  • arylcarbonyl (benzoyl) represents an "aryl” group as defined above at- , tached through a carbonyl group.
  • arylalkylcarbonyl (e.g. phenylcyclopropylcarbonyl, phenylethylcarbonyl and the like) represents an "arylalkyl” group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
  • alkylcarbonylalkyl represents an "alkylcarbonyl” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkylcarbonylalkyl represents an "arylalkylcarbonyl” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkylcarboxy e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy
  • alkylcarbonyl represents an "alkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
  • arylcarboxyalkyl e.g. phenylcarboxymethyl
  • arylcarbonyl represents an "arylcarbonyl” group defined above wherein the carbonyl is in turn attached through an oxygen bridge to an alkyl chain having the indicated number of carbon atoms.
  • arylalkylcarboxy e.g. benzylcarboxy, phenylcyclopropylcarboxy and the like
  • arylalkylcarbonyl represents an "arylalkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
  • alkylcarboxyalkyl represents an “alkylcarboxy” group attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkylcarboxyalkyl represents an "arylalkylcarboxy” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • alkylcarbonylamino (e.g. hexylcarbonylamino, cyclopentylcarbonyl- aminomethyl, methylcarbonylaminophenyl) represents an "alkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • arylalkylcarbonylamino e.g. benzylcarbonylamino and the like
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • alkylcarbonylaminoalkyl represents an "alkylcarbonylamino" group at- tached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • arylalkylcarbonylaminoalkyl represents an "arylalkylcarbonylamino” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • alkylcarbonylaminoalkylcarbonyl represents an alkylcarbonylaminoalkyl group attached through a carbonyl group.
  • the nitrogen atom may be further substituted with an "alkyl” or "aryl” group.
  • aryl represents an unsubstituted, mono-, di- or trisubstituted monocyclic, polycyclic, biaryl and heterocydic aromatic groups covalently attached at any ring 29 position capable of forming a stable covalent bond, certain preferred points of attachment being apparent to those skilled in the art (e.g., 3-indolyl, 4-imidazolyl).
  • the aryl substituents are independently selected from the group consisting of halo, nitro, cyano, trihalomethyl, C 1 -C 6 alkyl, aryl, arylC r C 6 alkyl, hydroxy, COR 5 , C r C 6 alkyloxy, C r C 6 alkyloxyC r C 6 alkyl, aryloxy, arylC 1 -C 6 alkyloxy, arylC T CealkyloxyC Cgalkyl, thio, C 1 -C 6 alkylthio, C- i -CealkylthioCi-Ce-alkyl, arylthio, arylC C 6 alkylthio, arylC r C 6 alkylthioC r C 6 alkyl, NR 8 R 9 , C 1 -C 6 alkylamino, C 1 -C 6 alkylaminoC 1 -C 6 alkyl, arylamino,
  • aryl includes but is not limited to phenyl, biphenyl, indenyl, fluorenyl, naphthyl (1-naphthyl, 2-naphthyl), pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imida- zolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-1-yl, 1 ,2,3-triazol-2-yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-
  • arylcarbonyl e.g. 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, oxa- zolylcarbonyl
  • arylalkylcarbonyl e.g. (2,3-dimethoxyphenyl)-propylcarbonyl, (2- chloronaphthyl)pentenylcarbonyl, imidazolylcyclo-pentylcarbonyl
  • the compounds of the present invention have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof.
  • salts of the compounds of formula 1 where a basic or acidic group is present in the structure, are also included within the scope of this invention.
  • an acidic substituent such as -COOH, 5-tetrazolyl or - P(O)(OH) 2 ⁇ there can be formed the ammonium, morpholinium, sodium, potassium, barium, calcium salt, and the like, for use as the dosage form.
  • an acidic salt such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroa- cetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartarate, fumarate, mandelate, benzoate, cinnamate, methanesulfonate, ethane sulfonate, pi- crate and the like, and include acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) and incorporated herein by reference, can be used as the dosage form.
  • an acidic salt such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroa- cetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartarate, fumarate, mandelate, benzoate,
  • ac- ceptable esters can be employed, e.g., methyl, tert-butyl, pivaloyloxymethyl, and the 32 like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
  • some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
  • terapéuticaally effective amount shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
  • A is together with the double bond in Formula 1a furanyl, thiophenyl, pyrrolyl, oxa- zolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1 ,2,3-oxadiazolyl, fu- razanyl or 1 ,2,3-triazolyl;
  • R 12 , R 13 , and R 14 are independently hydrogen, C,-C 6 alkyl, aryl, arylC 1 -C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C,- C 6 alkyl, aryl, arylC C 6 -alkyl, hydroxy, carboxy, carboxyC 1 -C 6 alkyl, C 1 - ' C 6 alkyloxy- carbonyl, aryloxycarbonyl, arylC r C 6 alkyloxycarbonyl, C r C 6 aikyloxy, C C 6 alkyl- oxyC r C 6 alkyl, aryloxy, arylC C 6 alkyloxy, arylC 1 -C 6 alkyl-oxyC 1 -C 6 alkyl, thio, C,- C 6 alkylthio, C r C 6 alkylthioC C 6 alkyl, arylthio, arylC C 6 alkylthioC 1 -C 6 alkylthio, arylC 1 -C 6 al
  • R 14 R « ° 35 wherein R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC r C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC C 6 alkyl, NR 7 R 8 , C 1 -C 6 alkyloxy;-whe- rein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C r C 6 alkyl, aryl, arylC ⁇ Cgalkyl, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C C 6 alkyl, aryl, arylC-j-Cgalkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C C 6 alkyl, aryl, arylC C 6 alkyl, C C 6 alkyl-carbonyl, arylcarbonyl, arylC r C 6 alkyl-carbonyl, C r C 6 alkyl-carboxy or a- rylC C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C C 6 aIkyl, aryl, arylC 1 -C 6 alkyl, hydroxy, C ⁇ C f -alkyloxy, arylC r C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl,
  • preferred compounds of the invention are compounds wherein R 16 and R 17 are hydrogen.
  • the invention will in its broadest aspect cover the following compounds: of Formula 1 : 36
  • A is together with the double bond in Formula 1 is aryl
  • R 1 is A H M .
  • R 12 O wherein R 12 , R 13 , and R 14 are independently hydrogen, C r Cgalkyl, aryl, arylC r C g alkyl and the alkyl and aryl groups are optionally substituted; 37
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C 6 alkyl, aryl, arylC r C 6 -alkyl, hydroxy, oxo, carboxy, carboxyC C 6 alkyl, C C 6 alkyloxycarbonyl, aryloxycarbonyl, arylC C 6 alkyloxycarbonyl, C r C 6 alkyloxy, C C 6 alkyloxyC Cgalkyl, aryloxy, arylC C 6 alkyloxy, arylC 1 -C 6 alkyloxyC 1 -C 6 alkyl, thio, C,- Cgalkylthio, C CgalkylthioC ⁇ Cgalkyl, arylthio, arylC 1 -C 6 alkylthio, arylC CgalkylthioC !
  • C r C 6 alkylaminoC r C 6 alkyl arylC 1 -CgalkylaminoC 1 -C 6 alkyl, di(arylC C 6 alkyl)amihoC 1 -C 6 alkyl, C r C 6 alkylcarbonyl, C 1 -C 6 alkylcarbonyl-C 1 -C 6 alkyl, arylC r C 6 alkylcarbonyl, arylC 1 -C 6 alkylcarbonylC 1 -C 6 alkyl, C r C 6 alkylcarboxy, C r C 6 alkylcarboxyC 1 -C 6 alkyl, arylcarboxy, arylcarboxyC r C 6 alkyl, arylC r C 6 alkylcarboxy, arylC 1 -C 6 alkylcarboxy, arylC 1 -C 6 alkylcarboxyC 1 -C 6 alkyl, C C 6
  • A is C C 8 alkyl, aryl or arylC C 6 alkyl;
  • B is amino, thio, SO, S0 2 or oxo;
  • C is C r C 8 alkyl, amino;
  • D is a chemical bond, amino or C C 8 alkyl wherein the alkyl and aryl groups are optionally substituted;
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC ⁇ Cgalkyl, NR 7 R 8 , C C 6 alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, Chalky!, aryl, arylC 1 -C 6 alkyl, C 1 -C 6 alkyloxy, C 1 -C 6 alkyl-oxyC 1 - C 6 alkyloxy, aryloxy, arylC.,-C 6 alkyloxy, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C 1 -C 6 alkyl, aryl, arylC ⁇ Cgalkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C r C 6 alkyl, adamantyl, aryl, a- rylC r C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC C 6 alkylcarbonyl, C r C 6 alkylcarboxy or arylC 1 -C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or
  • R 7 and R 8 are taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C C 6 alkyl, aryl, arylC C 6 alkyl, hydroxy, oxo, C r C 6 alkyloxy, arylC r C 6 alkyloxy, 39
  • R 9 and R 10 are independently selected from hydrogen, C r C 6 alkyl, aryl, arylC C 6 alkyl, C C 6 alkylcarbonyl, arylcarbonyl, arylC r C 6 alkylcarbonyl, C ⁇ C f -alkylcarboxy or arylC r C 6 alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membered amine, imide or lactam;
  • any optical iso- mer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • Particular preferred compounds of the invention are those compounds of formula I wherein R, is 5-tetrazolyl, i.e.
  • preferred compounds are those wherein R 5 is OH and R 4 is hydrogen.
  • the compounds are evaluated for biological activity with a truncated form of PTP1B (corresponding to the first 321 amino acids), which was expressed in E. coli and purified to apparent homogeneity using published procedures well-known to those skilled in the art.
  • the enzyme reactions are carried out using standard conditions essentially as described by Burke et al. (Biochemistry 35; 15989-15996 (1996)).
  • the assay conditions are as follows. Appropriate concentrations of the compounds of the invention are added to the reaction mixtures containing different concentrations of the substrate, p-nitrophenyl phosphate (range: 0.16 to 10 mM - final assay concen- tration).
  • the buffer used was 100 mM sodium acetate pH 5.5, 50 mM sodium chloride, 0.1 % (w/v) bovine serum albumin and 5 mM dithiothreitol (total volume 100 ml).
  • the reaction was started by addition of the enzyme and carried out in microtiter plates at 25 °C for 60 minutes. The reactions are stopped by addition of NaOH.
  • the enzyme activity was determined by measurement of the absorbance at 405 nm with appropriate corrections for absorbance at 405 nm of the compounds and p- nitrophenyl phosphate.
  • the data are analyzed using nonlinear regression fit to classical Michaelis Menten enzyme kinetic models. Inhibition is expressed as K; values in ⁇ M.
  • Table 1 45 The results of representative experiments are shown in Table 1 45
  • the compounds are evaluated for biological activity as regards their effect as inhibitors of PTP ⁇ in essentially the same way as described for inhibition of PTP1 B. Derived from their activity as evaluated above the compounds of the invention may be useful in the treatment of diseases selected from the group consisting of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance and obesity.
  • the compounds of the invention may be useful in the treatment of diseases selected from the group consi- sting of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • diseases selected from the group consi- sting of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • the compounds of the invention are prepared as illustrated in the following reaction scheme: 46
  • R 12 , R 13 , R 14 , and R 15 are independently selected from the group consisting of hydrogen, C r C 6 alkyl, aryl, arylC 1 -C 6 alkyl as defined above and the alkyl and aryl groups are optionally substituted as defined above; or R 12 - R ⁇ 3 .
  • R 14 . and R is are independently selected from
  • the above described four component Ugi reaction can be carried out by attaching any one of the components to a solid support.
  • the syn- thesis can be accomplished in a combinatorial chemistry fashion. 47
  • the present invention also has the objective of providing suitable topical, oral, and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs.
  • the composition for oral use may contain one or more agents selected from the group of sweetening agents, flavouring agents, colouring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations.
  • the tablets contain the acting ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable fpr the manufacture of tablets.
  • excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatine or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents such as corn starch or alginic acid
  • binding agents such as starch, gelatine or acacia
  • lubricating agents such as magnesium stearate, stearic acid or talc.
  • These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as
  • Formulations for oral use may be in the form of hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension.
  • expicients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hy- droxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylen- oxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e) a
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables. 49
  • compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • the compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phos- pholipids, such as cholesterol, stearylamine, or phosphatidyl-cholines.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula 1 are employed.
  • Dosage levels of the compounds of the present invention are of the order of about 0.5 mg to about 100 mg per kilogram body weight, with a preferred dosage range between about 20 mg to about 50 mg per kilogram body weight per day (from about 25 mg to about 5 g's per patient per day).
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for oral administration to humans may contain 5 mg to 1 g of an active compound with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • the dosage needs to be individualized by the clinician. 50
  • Wang-resin is polystyrene with a 4-hydroxymethylphenol ether linker.
  • Compounds used as starting material are either known compounds or compounds which can readily be prepared by methods known ger se.
  • 2-Aminothiophenes are prepared according to Gewald et al., Chem. Ber. 99: 94 (1966).
  • SP/MS 415 (M+, 12%), 372, 353, 299, 218, 190, 162, 109 (100%).
  • the blocks are shaken at 500 rpm for 3 days and then drained, washed and dried under vacuum overnight.
  • 1 ml solution of imidazol-1-yl-oxo-acetic acid tetf-butyl ester (200 ⁇ mol) in dichloromethane is dispensed into each well under nitrogen.
  • the blocks are shaken at 500 rpm overnight, drained, washed and dried under vacuum.
  • 1 ml of trifluoroace- tic acid/dichloromethane (1 :1) was dispensed into each well of the blocks and drained into a microtitre plate 30 min after it is dispensed.
  • X 1 indicate point of attachment for the R-group.
  • the percentage means the area of the peak of the HPLC at 220 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés, de nouvelles compositions, des méthodes d'utilisation et des méthodes de fabrication associées. Lesdits composés sont des inhibiteurs de protéine tyrosine phosphatases (PTPases) pharmacologiquement utiles, tels que PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR et HePTP ou analogues. Ces composés sont utiles dans le traitement du diabète du type I, du diabète du type II, de l'intolérance au glucose, de la résistance insulinique, de l'obésité, des dysfonctionnements immunitaires parmi lesquels les maladies auto-immunes entraînant un dysfonctionnement du système de coagulation, des maladies allergiques parmi lesquelles l'asthme, de l'ostéoporose, des troubles proliférants parmi lesquels le cancer et le psoriasis, des maladies entraînant une baisse ou une augmentation de la synthèse ou des effets des hormones de croissance, des maladies entraînant une baisse ou une augmentation de la synthèse des hormones ou cytokines qui régulent la libération d'hormones de croissance ou la réaction à ces hormones, des maladies cérébrales parmi lesquelles la maladie d'Alzheimer et la schizophrénie, et des maladies infectieuses.
PCT/DK1999/000123 1998-03-12 1999-03-11 Modulateurs de proteine tyrosine phosphatases (ptpases) WO1999046244A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99907334A EP1062204A1 (fr) 1998-03-12 1999-03-11 Modulateurs de proteine tyrosine phosphatases (ptpases)
JP2000535625A JP2002506058A (ja) 1998-03-12 1999-03-11 プロテインチロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター
AU27137/99A AU2713799A (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK0343/98 1998-03-12
DK34398 1998-03-12
DK47398 1998-04-03
DK0473/98 1998-04-03
DK9801561 1998-11-26
DK9800939 1998-11-26

Publications (1)

Publication Number Publication Date
WO1999046244A1 true WO1999046244A1 (fr) 1999-09-16

Family

ID=26063825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000123 WO1999046244A1 (fr) 1998-03-12 1999-03-11 Modulateurs de proteine tyrosine phosphatases (ptpases)

Country Status (2)

Country Link
AU (1) AU2713799A (fr)
WO (1) WO1999046244A1 (fr)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017516A2 (fr) * 1999-09-10 2001-03-15 Novo Nordisk A/S Procede d'inhibition de la proteine tyrosine phosphatase 1b et/ou de la proteine tyrosine phosphatase de lymphocytes et/ou d'autres ptpases possedant un reste aps en position 48
US6242453B1 (en) 1999-02-22 2001-06-05 Boehringer Ingelheim Pharmaceuticals, Inc Polycyclo heterocyclic derivatives as antiinflammatory agents
US6319921B1 (en) 1999-01-19 2001-11-20 Boerhinger Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compound as antiinflammatory agents
WO2002004459A1 (fr) * 2000-07-07 2002-01-17 Novo Nordisk A/S Modulateurs des proteines tyrosines phosphatases (ptpases)
US6358945B1 (en) 1999-03-12 2002-03-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2002085851A1 (fr) * 2001-04-19 2002-10-31 Sumitomo Pharmaceuticals Company, Limited Derive de type pyrrole
US6476023B1 (en) 1999-03-12 2002-11-05 Boehringen Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
WO2003006443A2 (fr) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives d'acide carboxylique, medicaments contenant ces composes, leur utilisation et leur production
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
WO2003033496A1 (fr) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Derives de beta-carboline en tant qu'inhibiteurs de ptp
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
WO2003082841A1 (fr) 2002-04-03 2003-10-09 Novartis Ag Derives 5-substitues 1,1-dioxo-`1,2,5!thiazolidine-3-one utilises en tant qu'inhibiteurs de ptpase 1b
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6753426B2 (en) 1999-07-09 2004-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph and process for preparing same
WO2004071447A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Utilisation de derives d'azoles substitues en tant qu'agents therapeutiques
WO2004071448A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
EP1510207A1 (fr) * 2002-06-05 2005-03-02 Institute of Medicinal Molecular Design, Inc. Medicaments therapeutiques destines au diabete
EP1512396A1 (fr) * 2002-06-05 2005-03-09 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de l'activation de ap-1 et de nfat
EP1512397A1 (fr) * 2002-06-06 2005-03-09 Institute of Medicinal Molecular Design, Inc. Derives hydroxyaryle o-substitues
EP1514544A1 (fr) * 2002-06-06 2005-03-16 Institute of Medicinal Molecular Design, Inc. Anti-allergique
EP1535609A1 (fr) * 2002-06-10 2005-06-01 Institute of Medicinal Molecular Design, Inc. Inhibiteur de l'activation de nf-kb
EP1535610A1 (fr) * 2002-06-10 2005-06-01 Institute of Medicinal Molecular Design, Inc. Agent therapeutique pour soigner le cancer
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
EP1555018A1 (fr) * 2002-06-11 2005-07-20 Institute of Medicinal Molecular Design, Inc. Traitements des maladies neurodegeneratives
WO2005085177A2 (fr) * 2004-03-01 2005-09-15 Spirogen Limited Acides amines
US7041669B2 (en) 2002-02-25 2006-05-09 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-benzofused urea compounds useful in treating cytokine mediated diseases
US7098240B2 (en) 2001-07-25 2006-08-29 Astrazeneca Ab Compounds
US7115624B1 (en) 1999-09-10 2006-10-03 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
US7125896B2 (en) 2001-07-25 2006-10-24 Astrazeneca Ab Thiophene carboxamide compounds as inhibitors of enzyme IKK-2
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US7265105B2 (en) 1998-08-27 2007-09-04 Spirogen Limited Pyrrolobenzodiazepines
US7358376B2 (en) 2000-02-12 2008-04-15 Astrazeneca Ab Substituted Thiophene compounds
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
US7407951B2 (en) 2002-11-14 2008-08-05 Spirogen Limited Pyrrolobenzodiazepines
US7429658B2 (en) 2003-09-11 2008-09-30 Spirogen Limited Synthesis of protected pyrrolobenzodiazepines
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
US7553868B2 (en) 2003-01-15 2009-06-30 Astrazeneca Ab Thiophene carboxamides as inhibitors of the enzyme IKK-2
US7572826B2 (en) 2003-01-15 2009-08-11 Astrazeneca Ab Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US7704924B2 (en) 1998-08-27 2010-04-27 Spirogen Limited Library of compounds comprising pyrrolobenzodiazepine moieties
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US7977477B2 (en) 2003-07-03 2011-07-12 Astex Therapeutics, Limited Benzimidazole derivatives and their use as protein kinase inhibitors
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9321774B2 (en) 2012-04-30 2016-04-26 Medimmune Limited Pyrrolobenzodiazepines
US9376440B2 (en) 2012-04-30 2016-06-28 Medimmune Limited Pyrrolobenzodiazepines as antiproliferative agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836541A (en) * 1972-09-27 1974-09-17 Upjohn Co 3-cyano-2-pyrryl oxamic acids
US3838166A (en) * 1972-09-27 1974-09-24 H Johnson Lower alkyl(3-cyano-pyrrol-2-yl)oxamates
GB1459065A (en) * 1974-03-15 1976-12-22 Upjohn Co Therapeutic thiophene derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836541A (en) * 1972-09-27 1974-09-17 Upjohn Co 3-cyano-2-pyrryl oxamic acids
US3838166A (en) * 1972-09-27 1974-09-24 H Johnson Lower alkyl(3-cyano-pyrrol-2-yl)oxamates
GB1459065A (en) * 1974-03-15 1976-12-22 Upjohn Co Therapeutic thiophene derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 105, No. 25, 22 December 1986, (Columbus, Ohio, USA), FEDOROVA I.N. et al., "Synthesis and Antiinflammatory Activity of the Derivatives of 2-Aminothiophene-5-Acetic Acids", page 759, Abstract No. 226239h; & KHIM.-FARM. ZH., 1986, 20(1), 39-45. *
CHEMICAL ABSTRACTS, Volume 110, No. 11, 13 March 1989, (Columbus, Ohio, USA), page 706, Abstract No. 95221z; & JP 63208583 A (YOSHINAGA JUNJI et al.) 30 August 1988. *
CHEMICAL ABSTRACTS, Volume 82, No. 23, 9 June 1975, (Columbus, Ohio, USA), ROBBA MAX et al., "Thienopyrimidine. IV. Synthesis and Study of Derivatives of Thiophene Amino Acids and Amino Ketones", page 577, Abstract No. 155996w; & BULL. SOC. CHIM. FR., 1974, 2864-2870. *
CHEMICAL ABSTRACTS, Volume 87, No. 3, 18 July 1977, (Columbus, Ohio, USA), RAZUVAEVA V.P. et al., "Amides and Hydrazides of Oxalic Acid XXV. Synthesis and Analgesic Activity of Esters of N-(4-Antipsy-ryl)Oxamic Acid", page 639, Abstract No. 23134g; & FARM. ZH., (Kiev), 1977, (1), 49-51. *
CHEMICAL ABSTRACTS, Volume 90, No. 9, 26 February 1979, (Columbus, Ohio, USA), BRIGGS FREDDA H. et al., "Pyrrole, Furan and Thiophene Oxamates as Potential Antiallergy Agents", page 27, Abstract No. 66596p; & J. PHARM. SCI., 1978, 67(5), 735-737. *
CHEMICAL ABSTRACTS, Volume 93, No. 10, 8 Sept. 1980, (Columbus, Ohio, USA), BEZUGLYI P.A. et al., "N-Heteryloxaminates 1-Adamantylammonium Having Diuretic Activity", page 391, Abstract No. 101484m; & OBRAZTSY, TOVARNYE ZNAKI, 1980, (7), 116-117. *
CHEMICAL ABSTRACTS, Volume 93, No. 24, 15 December 1980, (Columbus, Ohio, USA) BEZUGLYI P.A. et al., "Tert-Butylammonium N-Heteryloxamates Possessing Diuretic Activity", page 318, Abstract No. 225644h; & OBRAZTSY, TOVARNYE ZNAKI, 1980, (22), 144-145. *
CHEMICAL ABSTRACTS, Volume 94, No. 19, 11 May 1981, (Columbus, Ohio, USA), HONIGBERG IRWIN L. et al., "An In Vitro Study of 3-Cyano-4,5-Dimethyl-2-Pyrrolyloxamic Acid Metabolism", page 14, Abstract No. 149948p; & DRUG METAB. DISPOS., 1981, 9(1), 67-68. *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704924B2 (en) 1998-08-27 2010-04-27 Spirogen Limited Library of compounds comprising pyrrolobenzodiazepine moieties
US7265105B2 (en) 1998-08-27 2007-09-04 Spirogen Limited Pyrrolobenzodiazepines
US6372773B1 (en) 1999-01-19 2002-04-16 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6319921B1 (en) 1999-01-19 2001-11-20 Boerhinger Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compound as antiinflammatory agents
US6329415B1 (en) 1999-01-19 2001-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6333325B1 (en) 1999-01-19 2001-12-25 Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating cytokine mediated diseases or conditions
US6506748B2 (en) 1999-01-19 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6242453B1 (en) 1999-02-22 2001-06-05 Boehringer Ingelheim Pharmaceuticals, Inc Polycyclo heterocyclic derivatives as antiinflammatory agents
US7026476B2 (en) 1999-03-12 2006-04-11 Boehringer Ingelheim Pharmaceuticals, Inc. Intermediate arylamine compounds
US6656933B2 (en) 1999-03-12 2003-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6476023B1 (en) 1999-03-12 2002-11-05 Boehringen Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6358945B1 (en) 1999-03-12 2002-03-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7019006B2 (en) 1999-03-12 2006-03-28 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6660732B2 (en) 1999-03-12 2003-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6835832B2 (en) 1999-07-09 2004-12-28 Boehringer Ingelheim Pharmaceuticals, Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
US6894173B2 (en) 1999-07-09 2005-05-17 Boehringer Ingelheim Pharmaceuticals, Inc. Intermediates useful for synthesis of heteroaryl-substituted urea compounds, and processes of making same
US6774233B2 (en) 1999-07-09 2004-08-10 Boehringer Ingelheim Pharmaceuticals, Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
US6753426B2 (en) 1999-07-09 2004-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph and process for preparing same
WO2001017516A3 (fr) * 1999-09-10 2001-11-08 Novo Nordisk As Procede d'inhibition de la proteine tyrosine phosphatase 1b et/ou de la proteine tyrosine phosphatase de lymphocytes et/ou d'autres ptpases possedant un reste aps en position 48
US7115624B1 (en) 1999-09-10 2006-10-03 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
WO2001017516A2 (fr) * 1999-09-10 2001-03-15 Novo Nordisk A/S Procede d'inhibition de la proteine tyrosine phosphatase 1b et/ou de la proteine tyrosine phosphatase de lymphocytes et/ou d'autres ptpases possedant un reste aps en position 48
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
EP1743655A1 (fr) 2000-01-21 2007-01-17 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabétiques
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
US7358376B2 (en) 2000-02-12 2008-04-15 Astrazeneca Ab Substituted Thiophene compounds
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
WO2002004459A1 (fr) * 2000-07-07 2002-01-17 Novo Nordisk A/S Modulateurs des proteines tyrosines phosphatases (ptpases)
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US7196104B2 (en) 2000-08-15 2007-03-27 Amgen, Inc. Thiazolyl urea compounds and methods of uses
WO2002085851A1 (fr) * 2001-04-19 2002-10-31 Sumitomo Pharmaceuticals Company, Limited Derive de type pyrrole
US7220773B2 (en) 2001-04-19 2007-05-22 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
WO2003006443A2 (fr) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives d'acide carboxylique, medicaments contenant ces composes, leur utilisation et leur production
WO2003006443A3 (fr) * 2001-07-11 2003-05-01 Boehringer Ingelheim Pharma Derives d'acide carboxylique, medicaments contenant ces composes, leur utilisation et leur production
US7956084B2 (en) 2001-07-25 2011-06-07 Astrazeneca Ab Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2
US7125896B2 (en) 2001-07-25 2006-10-24 Astrazeneca Ab Thiophene carboxamide compounds as inhibitors of enzyme IKK-2
US7098240B2 (en) 2001-07-25 2006-08-29 Astrazeneca Ab Compounds
WO2003033496A1 (fr) * 2001-10-19 2003-04-24 Transtech Pharma, Inc. Derives de beta-carboline en tant qu'inhibiteurs de ptp
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
US7041669B2 (en) 2002-02-25 2006-05-09 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-benzofused urea compounds useful in treating cytokine mediated diseases
WO2003082841A1 (fr) 2002-04-03 2003-10-09 Novartis Ag Derives 5-substitues 1,1-dioxo-`1,2,5!thiazolidine-3-one utilises en tant qu'inhibiteurs de ptpase 1b
EP2341049A1 (fr) 2002-04-03 2011-07-06 Novartis AG Derives 5-substitues 1,1-dioxo-[1,2,5]thiazolidine-3-one utilises en tant qu'inhibiteurs de PTPASE 1B
EP1510207A1 (fr) * 2002-06-05 2005-03-02 Institute of Medicinal Molecular Design, Inc. Medicaments therapeutiques destines au diabete
EP1510207A4 (fr) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc Medicaments therapeutiques destines au diabete
EP1512396A4 (fr) * 2002-06-05 2008-12-31 Inst Med Molecular Design Inc Inhibiteurs de l'activation de ap-1 et de nfat
EP1512396A1 (fr) * 2002-06-05 2005-03-09 Institute of Medicinal Molecular Design, Inc. Inhibiteurs de l'activation de ap-1 et de nfat
EP1512397A4 (fr) * 2002-06-06 2009-01-07 Inst Med Molecular Design Inc Derives hydroxyaryle o-substitues
EP1512397A1 (fr) * 2002-06-06 2005-03-09 Institute of Medicinal Molecular Design, Inc. Derives hydroxyaryle o-substitues
JPWO2003103665A1 (ja) * 2002-06-06 2005-10-06 株式会社医薬分子設計研究所 抗アレルギー薬
JP4660674B2 (ja) * 2002-06-06 2011-03-30 株式会社医薬分子設計研究所 抗アレルギー薬
EP1514544A4 (fr) * 2002-06-06 2009-01-07 Inst Med Molecular Design Inc Anti-allergique
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
EP1514544A1 (fr) * 2002-06-06 2005-03-16 Institute of Medicinal Molecular Design, Inc. Anti-allergique
EP1535610A1 (fr) * 2002-06-10 2005-06-01 Institute of Medicinal Molecular Design, Inc. Agent therapeutique pour soigner le cancer
EP1535609A1 (fr) * 2002-06-10 2005-06-01 Institute of Medicinal Molecular Design, Inc. Inhibiteur de l'activation de nf-kb
EP1535609A4 (fr) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Inhibiteur de l'activation de nf-kb
EP1535610A4 (fr) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc Agent therapeutique pour soigner le cancer
EP1555018A4 (fr) * 2002-06-11 2009-01-07 Inst Med Molecular Design Inc Traitements des maladies neurodegeneratives
EP1555018A1 (fr) * 2002-06-11 2005-07-20 Institute of Medicinal Molecular Design, Inc. Traitements des maladies neurodegeneratives
US7407951B2 (en) 2002-11-14 2008-08-05 Spirogen Limited Pyrrolobenzodiazepines
US7572826B2 (en) 2003-01-15 2009-08-11 Astrazeneca Ab Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2
US7553868B2 (en) 2003-01-15 2009-06-30 Astrazeneca Ab Thiophene carboxamides as inhibitors of the enzyme IKK-2
WO2004071447A3 (fr) * 2003-02-12 2004-12-23 Transtech Pharma Inc Utilisation de derives d'azoles substitues en tant qu'agents therapeutiques
WO2004071447A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Utilisation de derives d'azoles substitues en tant qu'agents therapeutiques
WO2004071448A3 (fr) * 2003-02-12 2004-10-14 Transtech Pharma Inc Derives d'azole substitues comme agents therapeutiques
WO2004071448A2 (fr) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
US8513302B2 (en) 2003-04-03 2013-08-20 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US8455652B2 (en) 2003-04-03 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitors for the soluble epoxide hydrolase
US7977477B2 (en) 2003-07-03 2011-07-12 Astex Therapeutics, Limited Benzimidazole derivatives and their use as protein kinase inhibitors
US7429658B2 (en) 2003-09-11 2008-09-30 Spirogen Limited Synthesis of protected pyrrolobenzodiazepines
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
WO2005085177A3 (fr) * 2004-03-01 2005-11-17 Spirogen Ltd Acides amines
WO2005085177A2 (fr) * 2004-03-01 2005-09-15 Spirogen Limited Acides amines
US8476043B2 (en) 2004-10-20 2013-07-02 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8778936B2 (en) 2004-12-30 2014-07-15 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
US9321774B2 (en) 2012-04-30 2016-04-26 Medimmune Limited Pyrrolobenzodiazepines
US9376440B2 (en) 2012-04-30 2016-06-28 Medimmune Limited Pyrrolobenzodiazepines as antiproliferative agents
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9499497B2 (en) 2012-11-20 2016-11-22 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase

Also Published As

Publication number Publication date
AU2713799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
WO1999046244A1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
US6225329B1 (en) Modulators of protein tyrosine phosphatases (PTPases)
EP1080095B1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
US6410586B1 (en) Modulators of protein tyrosine phosphatases (PTPases)
US20020165398A1 (en) Modulators of protein tyrosine phosphatases (PTPases)
US6169087B1 (en) Modulators of protein tyrosine phosphatases (PTPases)
US20020019412A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
WO1999046236A1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
WO1999046267A1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
EP1062218A1 (fr) MODULATEURS DE PROTEINE TYROSINE PHOSPHATASES (PTPases)
EP1214324B1 (fr) MODULATEURS DE PROTEINE TYROSINE PHOSPHATASE (PTPases)
EP1214325B1 (fr) MODULATEURS DE PROTEINES TYROSINE PHOSPHATAGES (PTPases)
US5972978A (en) Modulators of molecules with phosphotyrosine recognition units
US20050119332A1 (en) Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
EP1080068A1 (fr) Modulateurs de proteine tyrosine phosphatases
JP2004500308A5 (fr)
US6410556B1 (en) Modulators of protein tyrosine phosphateses (PTPases)
JP2000509373A (ja) ホスホチロシン認識ユニットを有する分子のモジュレーター
EP1062204A1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
EP1062199A1 (fr) Modulateurs de proteine tyrosine phosphatases (ptpases)
AU2713999A (en) Modulators of protein tyrosine phosphatases
CZ20003229A3 (cs) Sloučenina a její použití, farmaceutická kompozice a její použití a způsob úpravy aktivity, izolace, detekce, stanovení množství a funkce proteinových tyrosinfosfatas
MXPA00008921A (es) Moduladores de las proteinas tirosina fosfatasas.
CZ20003228A3 (cs) Modulátory proteinu tyrosin fosfatázy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999907334

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999907334

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999907334

Country of ref document: EP